Prague

• An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian … Ended
  2023-508149-42-00 3 2024-07-16 Infertility in women undergoing assisted reproductive technologies (AR
• A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa … Ended
  2023-508377-82-00 10 2024-06-27 Hidradenitis Suppurativa (HS)
• Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsal … Ended
  2024-513665-40-00 2 2024-06-25 not applicable (submitted trial is a bioequivalence in healthy subject
• An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulation Ended
  2023-507630-25-00 3 2024-06-14 Infertility in women undergoing assisted reproductive technologies (AR
• An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive … Ended
  2023-506570-12-01 4 2024-06-13 Cognitive disorder
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2023-506557-38-00 5 2024-05-16 Dermatitis atopic
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended
  2023-506655-19-00 4 2024-05-16 Ulcerative Colitis (UC)
• An open label, randomized, two-period, two-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Val … Ended
  2024-511570-77-00 2 2024-05-13 not applicable (submitted trial is a bioavailability study in healthy
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject … Ended
  2023-505842-24-00 5 2024-05-07 Moderate to Severe Plaque Psoriasis
• A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants with Cirrhosis-ZEAL-UNLOCK Ended
  2023-506893-11-00 4 2024-04-19 Cirrhosis of the liver is a condition in which the liver is scarred an
• Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Ended
  2023-510127-30-00 1 2024-04-17 Relapsing Remitting Multiple Sclerosis (RRMS)
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Ended
  2023-506127-29-00 4 2024-03-05 Diabetic Peripheral Neuropathy
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 4 2024-03-01 Early Alzheimer’s Disease with Biomarkers of Inflammation
• Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis. Ended
  2023-504346-66-00 4 2024-02-14 Dermatitis atopic
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• A Phase 2a Study to Evaluate Setanaxib in Patients with Alport Syndrome Ended
  2023-505292-73-00 4 2024-01-10 Alport syndrome
• A research study to see how a new weekly insulin, insulin icodec when given along with semaglutide helps in reducing the blood sugar level i … Ended
  2022-502717-28-00 5 2024-01-09 Diabetes Type 2
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis

Showing 697–720 of 847 trials